FindTrial
Sign In

CART cell bridging allogeneic hematopoietic stem cell transplantation for treatment of refractory / relapsed B cell non Hodgkin's lymphoma: non blind, non controlled, single center clinical trial

CART cell bridging allogeneic hematopoietic stem cell transplantation for treatment of refractory / relapsed B cell non Hodgkin's lymphoma: non blind, non controlled, single center clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-16009027
Enrollment
Unknown
Registered
2016-08-15
Start date
2017-05-10
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CD19 positive expression of refractory / relapsed B cell non Hodgkin's lymphoma

Interventions

Case series:CART cells bridging allogeneic hematopoietic stem cell transplantation

Sponsors

Xinqiao Hospital, Third Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Male and female aged under 55 years old; 2. with CD19 expression positive refractory / relapsed non Hodgkin's lymphoma and no effective treatment modality for selected patients; 3. estimated survival tiem less than 3 months; 4. ECOG=2 scores; 5. No serious systemic organ dysfunction.

Exclusion criteria

Exclusion criteria: 1) Uncontrolled positive infection, HBV or HCV positive; 2) Patients taked part in other cell immunotherapy trials.

Design outcomes

Primary

MeasureTime frame
disease-Free survival of 1 years;—

Secondary

MeasureTime frame
Hematopoietic reconstitution time;ratio of GVHD;Complication of therapy;ratio of relapse;overall survival of 1years;—

Countries

China

Contacts

Public ContactLiu Yao

Center of Hematology, Xinqiao Hospital, Third Military Medical University

648283926@qq.com+86 13228684685

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026